Alector, Inc. Stock

Equities

ALEC

US0144421072

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-07-19 pm EDT 5-day change 1st Jan Change
5.83 USD 0.00% Intraday chart for Alector, Inc. +5.23% -26.94%
Sales 2024 * 63.52M Sales 2025 * 118M Capitalization 562M
Net income 2024 * -189M Net income 2025 * -129M EV / Sales 2024 * 0.9 x
Net cash position 2024 * 505M Net cash position 2025 * 576M EV / Sales 2025 * -0.12 x
P/E ratio 2024 *
-2.95 x
P/E ratio 2025 *
-3.87 x
Employees 244
Yield 2024 *
-
Yield 2025 *
-
Free-Float 91.02%
More Fundamentals * Estimated data
Dynamic Chart

Latest transcript on Alector, Inc.

1 week+5.23%
Current month+28.41%
1 month+36.85%
3 months+14.54%
6 months-0.85%
Current year-26.94%
More quotes
1 week
5.48
Extreme 5.48
6.09
1 month
4.16
Extreme 4.16
6.09
Current year
4.11
Extreme 4.11
8.90
1 year
3.66
Extreme 3.66
9.07
3 years
3.66
Extreme 3.66
35.14
5 years
3.66
Extreme 3.66
43.32
10 years
3.66
Extreme 3.66
43.32
More quotes
Managers TitleAgeSince
Founder 68 13-04-30
President 56 21-12-14
Director of Finance/CFO 51 22-02-06
Members of the board TitleAgeSince
Chairman 75 18-09-30
Director/Board Member 70 18-09-30
Founder 68 13-04-30
More insiders
Date Price Change Volume
24-07-19 5.83 0.00% 707,975
24-07-18 5.83 0.00% 731,373
24-07-17 5.83 -4.11% 1,740,705
24-07-16 6.08 +6.11% 631,312
24-07-15 5.73 +3.43% 520,789

Delayed Quote Nasdaq, July 19, 2024 at 04:00 pm EDT

More quotes
Alector, Inc. is a clinical-stage biotechnology company. The Company is focused on immuno-neurology, a novel therapeutic approach for the treatment of neurodegeneration diseases. The Company is engaged in developing therapies designed to counteract these pathologies simultaneously by restoring healthy immune function to the brain. Its research and drug discovery platform leverages human genetic datasets, advanced tools in bioinformatics and imaging, and insights in neurodegeneration and immunology to identify immune system. Its product candidates: latozinemab (AL001), AL002, and AL101, are in clinical development. Its immune-neurology product candidates are supported by biomarkers and seek to treat indications, including Alzheimer’s disease and genetically defined frontotemporal dementia patient populations. Its first product candidate, latozinemab, is a human recombinant monoclonal antibody that increases the levels of progranulin (PGRN) in the brains of FTD-GRN patients.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
5.83 USD
Average target price
15.44 USD
Spread / Average Target
+164.91%
Consensus